By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today said it has received clearance from the US Food and Drug Administration for its Tissue of Origin test for formalin-fixed paraffin embedded tissue.

The Pathwork Tissue of Origin test can now be broadly used on common clinical FFPE tumor specimens from both community and research hospitals, Pathwork Diagnostics said in a statement. The clearance also clears the way for additional FFPE-based cancer tests on its platform, the company added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.